Tremelimumab,Durvalumab 
astrazeneca
[]
 tremelimumab &amp; durvalumab as neoadjuvant treatment for msi resectable #gastriccancer -gi 2023 infinity phs-ii, 15 pts "chalabi plot"... pcr 60%, major response: 80% 2pts with disease progression safe &amp; promising 
Physician-scientist, focused on translational research in hepatobiliary cancer and precision medicine